Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

clarkhealthcommunications

- PMLiVE

Novartis shares positive results for spinal muscular atrophy gene therapy Zolgensma

The company said the results support the use of the one-time therapy in older and heavier children

- PMLiVE

Drugmakers submit counteroffers to US Medicare pricing negotiations

New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026

- PMLiVE

Incentivising innovation in antibiotics

Why current intellectual property and regulatory data exclusivity systems are failing to stimulate innovation in the field of antibiotics and antimicrobials

- PMLiVE

Fool me once

But just once – after that, you’re on your own

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Mtech Access – Powered by Petauri™

- PMLiVE

GSK’s Jemperli combination recommended by NICE as first-line endometrial cancer treatment

Approximately 580 patients will now be eligible for treatment with the PD-1 inhibitor

Bayer symbol

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

- PMLiVE

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Around 400 stem cell or bone marrow transplant patients will develop the condition each year in England

- PMLiVE

Pfizer’s RSV vaccine Abrysvo shown to maintain strong efficacy in older adults

RSV infections account for up to 160,000 hospitalisations among older adults each year in the US

- PMLiVE

First UK cancer patients receive Moderna’s experimental mRNA therapy

The Mobilize trial is evaluating mRNA-4359 in cancers including melanoma and lung cancer

- PMLiVE

Big truths, small spaces

The dragonfly teaches us something about commercial excellence

- PMLiVE

Johnson & Johnson’s Rybrevant granted FDA approval for lung cancer indications

The drug was previously authorised for use by the US regulator under the accelerated approval pathway

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links